

Online supplementary table S2. Characteristics of included studies and assessment of risk of bias: authors' judgment about each risk of bias item for each included study

Author	Year	Study type	Country	EAM	Sample size	Risk of bias				
						Sampling frame	Case definition for AS	Selection of patients	Response	Case definition for EAM
Aaron ¹	1985	Cross-sectional	USA	Uveitis	59	?	-	-	?	?
Aggarwal ²	2005	Cross-sectional	India	Uveitis	150	?	-	-	?	+
Aggarwal ³	2009	Retrospective cohort	India	Uveitis	70	+	+	-	?	+
Agrawal ⁴	2007	Cross-sectional	India	Uveitis	162	?	+	?	?	?
al Attia ⁵	1998	Retrospective cohort	United Arab Emirates	Uveitis	28	+	+	+	?	+
Almodovar ⁶	2009	Cross-sectional	Spain	Psoriasis IBD	842	+	+	+	?	+
Aloush ⁷	2007	Cross-sectional	Israel	IBD	36	+	+	+	?	-
Amor-Dorado ⁸	2011	Cross-sectional	Spain	Uveitis	50	+	+	-	?	+
Arends ⁹	2011	Retrospective cohort	Netherlands	Uveitis Psoriasis IBD	220	+	+	-	?	?
Askari ¹⁰	2000	Cross-sectional	Jordan	Uveitis	22	+	+	+	?	+
Atagunduz ¹¹	2010	Cross-sectional	Turkey	Uveitis	235	+	+	-	?	-
Aydin ¹²	2008	Cross-sectional	Turkey	Uveitis	175	+	+	?	?	?
Baek ¹³	2004	Cross-sectional	Korea	Uveitis	67	+	+	-	?	+
Bakland ¹⁴	2005	Retrospective-cohort	Norway	Psoriasis IBD	534	+	+	+	+	+

Beyeler ¹⁵	1996	Cross-sectional	UK	Uveitis Psoriasis IBD	54	+	+	?	?	+
Bodur ¹⁶	2012	Cross-sectional	Turkey	Uveitis Psoriasis IBD	1381	+	+	?	?	?
Bontempo ¹⁷	2006	Cross-sectional	Brasil	Uveitis	75	+	?	+	?	?
Boonen ¹⁸	2001	Cross-sectional	Netherlands	IBD	658	+	?	+		-
Boonen ¹⁹	2003	Retrospective cohort	Netherlands, Belgium, France	IBD	209	+	+	+	?	-
Boonen ²⁰	2009	Cross-sectional	Belgium	Uveitis Psoriasis IBD	619	+	+	+	?	+
Brandt ²¹	2003	Cross-sectional	Germany	Uveitis	134	+	+	?	?	+
Brandt ²²	2003	Randomized controlled trial	Germany	Uveitis	30	?	+	-	-	?
Braun ²³	2002	Randomized controlled trial	Germany	Uveitis	69	?	+	-	?	?
Breban ²⁴	2008	Randomized controlled trial	France	Uveitis Psoriasis	247	?	+	-	?	?
Breban ²⁵	2002	Non-randomized controlled trial	France	Uveitis Psoriasis IBD	50	+	+	-	?	?
Bremander ²⁶	2011	Retrospective cohort	Sweden	Uveitis Psoriasis IBD	935	+	?	+	?	+
Brophy ²⁷	2001	Retrospective cohort	UK	Uveitis Psoriasis IBD	4953	+	-	+	?	+
Brophy ²⁸	2002	Retrospective cohort	UK	Uveitis Psoriasis	507	+	-	?	?	+

				IBD						
Burgos ²⁹	1989	Retrospective cohort	Mexico	Uveitis	40	+	-	?	+	+
Calin ³⁰	1993	Cross-sectional	UK	Uveitis Psoriasis IBD	320	+	-	?	?	-
Cansu ³¹	2011	Cross-sectional	Turkey	Uveitis Psoriasis IBD	102	+	+	?	?	-
Carbone ³²	1992	Cross-sectional	USA	Psoriasis IBD	158	+	+	+	?	+
Chavan ³³	2011	Cross-sectional	India	Uveitis	81	+	+	?	?	?
Chen ³⁴	2007	Cross-sectional	Taiwan	Uveitis	146	+	+	+	?	-
Chen ³⁵	2011	Cross-sectional	Taiwan	Uveitis	531	+	+	+	?	+
Chen ³⁶	2010	Cross-sectional	Taiwan	Uveitis	120	+	+	+	?	+
Chen ³⁷	2012	Cross-sectional	Taiwan	Uveitis	460	+	+	+	?	+
Choi ³⁸	2008	Cross-sectional	South-Korea	Uveitis	30	+	-	-	?	?
Cinar ³⁹	2010	Cross-sectional	Turkey	Uveitis Psoriasis	95	+	+	-	+	?
Coates ⁴⁰	2008	Retrospective cohort	UK	Psoriasis IBD	119	+	+	-	?	?
Collantes ⁴¹	2007	Prospective cohort	Spain	Uveitis	842	+	+	+	?	+
Cooper ⁴²	1994	Retrospective cohort	USA	Uveitis	158	+	+	+	?	+
Davis ⁴³	2003	Randomized controlled trial	USA, Canada, Germany, France, the Netherlands	Uveitis Psoriasis IBD	277	?	+	-	?	?
De Juan ⁴⁴	1999	Cross-sectional	Spain	Uveitis	46	?	+	?	?	?
De Vries ⁴⁵	2010	Cross-sectional	The	Uveitis	78	+	+	-	?	?

			Netherlands	IBD						
Dijkmans ⁴⁶	2009	Open label study	8 European countries	Uveitis IBD	81	?	+	-	?	?
Donelly ⁴⁷	1994	Cross-sectional	UK	Psoriasis IBD	87	+	?	+	?	+
Doran ⁴⁸	2003	Retrospective cohort	UK	Uveitis Psoriasis IBD	311	+	-	+	?	+
Dougados ⁴⁹	2009	Randomized controlled trial	France, Germany, Netherlands, Hungary	Uveitis Psoriasis IBD	82	+	+	-	?	?
Dougados ⁵⁰	2011	Randomized controlled trial	France	Uveitis Psoriasis IBD	181	+	+	?	?	+
Durmus ⁵¹	2009	Cross-sectional	Turkey	Uveitis	80	+	+	?	?	?
Edmunds ⁵²	1991	Cross-sectional	UK	Uveitis	1331	+	?	?	?	-
El Maghraoui ⁵³	2003	Cross-sectional	Turkey	Uveitis Psoriasis IBD	31	+	+	+	?	+
El Maghraoui ⁵⁴	1999	Cross-sectional	France	Psoriasis IBD	80	?	+	-	?	+
El Mansouri ⁵⁵	2009	Cross-sectional	Morocco	Uveitis	117	+	+	?	?	+
Elswood ⁵⁶	1987	Cross-sectional	Sweden UK	Uveitis	2346	-	?	+	?	-
Eustace ⁵⁷	1993	Retrospective cohort	Ireland	Uveitis	83	?	+	?	?	?
Feldtkeller ⁵⁸	2008	Cross-sectional	Germany	Uveitis Psoriasis IBD	908	-	?	+	?	-
Feldtkeller ⁵⁹	2003	Cross-sectional	Germany Austria	Uveitis Psoriasis	944	-	?	?	-	-

				IBD						
Feldtkeller ⁶⁰	2006	Cross-sectional	Germany Austria	Uveitis Psoriasis IBD	1071	⊖	?	?	⊖	⊖
Fisher ⁶¹	1990	Cross-sectional	UK	Uveitis	33	?	⊖	⊖	+	+
Geirsson ⁶²	2010	Cross-sectional	Iceland	Uveitis	223	+	+	⊖	+	+
Gerard ⁶³	2008	Retrospective cohort	France	Uveitis Psoriasis IBD	101	+	+	⊖	?	+
Gladman ⁶⁴	1993	Cross-sectional	Canada	Uveitis	40	⊖	+	⊖	?	?
Glaznovic ⁶⁵	2011	Cross-sectional	Croatia	Uveitis IBD	49	+	+	?	?	?
Goh ⁶⁶	2008	Cross-sectional	UK	Uveitis	34	+	+	⊖	?	?
Gonzalez ⁶⁷	2001	Cross-sectional	Spain	Uveitis	105	+	+	?	?	?
Gran ⁶⁸	1984	Cross-sectional	Norway	Uveitis	101	+	⊖	?	?	+
Gran ⁶⁹	1985	Retrospective cohort	Norway	Uveitis	126	+	⊖	⊖	?	?
Gran ⁷⁰	1995	Cross-sectional	Norway	Uveitis	100	+	+	⊖	?	+
Gunal ⁷¹	2008	Cross-sectional	Turkey	Uveitis	112	+	+	+	?	+
Guo ⁷²	2009	Cross-sectional	China	Uveitis	240	+	+	+	?	+
Haibel ⁷³	2005	Open label study	Germany	Uveitis Psoriasis IBD	20	?	+	⊖	?	⊖
Haibel ⁷⁴	2008	Open label study	Germany	Uveitis Psoriasis IBD	101	+	+	⊖	?	?
Hanova ⁷⁵	2010	Retrospective cohort	Czech	Uveitis IBD	48	+	+	+	⊖	+
Hascelik ⁷⁶	2009	Cross-sectional	Turkey	IBD	25	+	+	⊖	⊖	+
Harfouch ⁷⁷	2011	Cross-sectional	Syria	Uveitis	50	+	+	⊖	?	?

Helliwel ⁷⁸	1998	Cross-sectional	UK	Uveitis	91	+	+	+	?	?
Heuft-Doorenbosch ⁷⁹	2004	Prospective cohort	Netherlands Belgium France	Uveitis Psoriasis IBD	217	+	+	+	?	+
Huang ⁸⁰	2011	Cross-sectional	China	Uveitis IBD	330	+	+	?	-	+
Ho ⁸¹	2012	Retrospective cohort	Taiwan	Uveitis	1503	+	+	-	?	+
Hukuda ⁸²	2001	Cross-sectional	Japan	Uveitis Psoriasis IBD	654	+	-	?	?	+
Inman ⁸³	2008	Randomized controlled trial	USA Canada Europe Asia	Uveitis Psoriasis IBD	356	+	+	-	+	?
Inman ⁸⁴	2010	Randomized controlled trial	Canada	Uveitis Psoriasis IBD	76	+	+	-	+	?
Islam ⁸⁵	1995	Cross-sectional	Japan	Uveitis	40	+	-	-	?	?
Jaakkola ⁸⁶	2006	Cross-sectional	Finland	Uveitis Psoriasis IBD	270	+	+	?	+	-
Jang ⁸⁷	2011	Prospective cohort	USA	Uveitis IBD	769	+	+	?	?	-
Jimenez ⁸⁸	2011	Retrospective cohort	Mexico	Uveitis	93	+	?	+	?	+
Jimenez ⁸⁹	1997	Retrospective cohort	Mexico	Uveitis	281	+	-	?	?	+
Jimenez ⁹⁰	1993	Retrospective cohort	Mexico	Uveitis	84	+	-	-	?	+
Jung ⁹¹	2007	Cross-sectional	South-Korea	Uveitis IBD	38	+	+	?	?	?

Jung ⁹²	2011	Cross-sectional	South-Korea	Uveitis	223	+	+	?	?	?
Kaijzel ⁹³	1999	Cross-sectional	Netherlands	Uveitis	86	?	-	?	?	?
Kidd ⁹⁴	1988	Cross-sectional	UK	Uveitis	105	+	+	-	?	+
Kim ⁹⁵	2009	Retrospective cohort	South-Korea	Uveitis	490	?	+	?	?	+
Kim ⁹⁶	2010	Cross-sectional	South-Korea	Uveitis IBD	830	+	+	?	?	+
Kim ⁹⁷	2007	Cross-sectional	South-Korea	Uveitis	544	+	+	?	?	+
Klinkberg ⁹⁸	2012	Cross-sectional	Sweden	Uveitis	205	+	+	-	-	-
Koh ⁹⁹	1993	Cross-sectional	South-Korea	Uveitis	38	+	-	?	?	+
Koh ¹⁰⁰	1998	Cross-sectional	Singapore	Uveitis	150	+	-	?	?	+
Lee ¹⁰¹	2001	Prospective cohort	South-Korea	Uveitis	112	+	+	-	?	+
Lee ¹⁰²	1997	Cross-sectional	South-Korea	Uveitis	24	+	+	-	?	?
Lee ¹⁰³	2005	Cross-sectional	South-Korea	Uveitis	61	+	+	-	?	+
Lee ¹⁰⁴	2002	Retrospective cohort	South-Korea	Uveitis	212	+	+	-	?	+
Lin ¹⁰⁵	2009	Cross-sectional	Taiwan	Uveitis IBD	122	+	+	-	?	+
Magrey ¹⁰⁶	2010	Retrospective cohort	USA	Uveitis	490	?	+	?	?	+
Maki-ikola ¹⁰⁷	1996	Cross-sectional	Finland	Uveitis	98	?	?	?	?	?
Maksymowych ¹⁰⁸	1997	Cross-sectional	Canada	Uveitis Psoriasis IBD	100	+	+	-	?	?
Maksymowych ¹⁰⁹	1995	Retrospective cohort	Canada Taiwan	Uveitis Psoriasis IBD	271	+	+	?	?	+
Maksymowych ¹¹⁰	1997	Cross-sectional	Mexico	Uveitis	170	?	+	-	?	?
Maksymowych	2006	Cross-sectional	Canada	Uveitis	263	+	+	+	?	?

111			Colombia Australia	Psoriasis IBD						
Maksymowych ¹¹²	1995	Retrospective cohort	Canada	Uveitis Psoriasis IBD	86	+	+	+	+	+
Maksymowych ¹¹³	2010	Randomized-controlled trial	Canada	Uveitis Psoriasis IBD	36	?	+	-	?	?
Maksymowych ¹¹⁴	2000	Cross-sectional	Mexico	Uveitis Psoriasis IBD	58	+	+	-	?	+
Maksymowych ¹¹⁵	1994	Cross-sectional	Canada	Uveitis Psoriasis IBD	125	?	+	?	?	?
Martindale ¹¹⁶	2006	Prospective cohort	UK	Uveitis Psoriasis IBD	89	+	+	-	?	+
Mierau ¹¹⁷	1988	Cross-sectional	Germany	Uveitis	240	+	-	-	?	+
Muntean ¹¹⁸	2011	Cross-sectional	Romania	Uveitis	44	+	+	-	?	+
Nazarinia ¹¹⁹	2009	Prospective cohort	Iran	Uveitis	98	+	+	?	+	+
Ozgcimen ¹²⁰	2009	Cross-sectional	Turkey	Uveitis Psoriasis IBD	279	+	+	+	+	+
Paardt ¹²¹	2002	Cross-sectional	Netherlands	Uveitis	165	+	+	-	-	+
Park ¹²²	2009	Retrospective cohort	Korea	Uveitis	143	+	+	-	?	+
Pham ¹²³	2006	Cross-sectional	Australia, Belgium, Canada, France, Germany, Italy,	IBD	1207	+	?	-	?	-

			Mexico, Netherlands, Spain, UK							
Piergiacomi ¹²⁴	1988	Retrospective cohort	Italy	Uveitis	368	+	?	+	?	+
Pimentel-Santos ¹²⁵	2012	Cross-sectional	Portugal	Uveitis Psoriasis IBD	369	+	+	+	?	-
Prakash ¹²⁶	1984	Cross-sectional	India	Uveitis	51	+	-	-	?	+
Prati ¹²⁷	2011	Cross-sectional	France	Uveitis Psoriasis IBD	46	+	+	-	?	+
Rahman ¹²⁸	2008	Cross-sectional	Canada	Psoriasis IBD	796	+	+	?	?	?
Robertson ¹²⁹	2004	Prospective cohort	UK	Uveitis Psoriasis IBD	74	+	+	?	-	+
Rudwaleit ¹³⁰	2009	Cross-sectional	Germany	Uveitis Psoriasis IBD	236	+	+	-	?	+
Rudwaleit ¹³¹	2009	Open label	Europe	Uveitis Psoriasis IBD	1250	+	+	-	?	-
Sambrook ¹³²	1985	Retrospective cohort	Australie	Uveitis	74	+	-	?	?	+
Sampaio ¹³³	2006	Retrospective cohort	Brazil	Uveitis	207	+	+	?	?	+
Sampaio ¹³⁴	2001	Retrospective cohort	Brazil	Uveitis	147	+	+	-	+	+
Sanmarti ¹³⁵	1987	Cross-sectional	Spain	Uveitis	51	?	-	-	?	+
Saougou ¹³⁶	2010	Open label study	Greece	Uveitis	40	+	+	-	?	?

Shukla ¹³⁷	2010	Open label study	India	Uveitis	52	?	+	-	?	+
Singh ¹³⁸	2008	Retrospective cohort	India	Uveitis	271	+	+	+	?	+
Skare ¹³⁹	2007	Cross-sectional	Brasil	Uveitis	45	+	-	?	?	+
Stone ¹⁴⁰	2001	Open label study	Canada	Uveitis	21	+	+	-	?	+
Temekonidis ¹⁴¹	2003	Open label study	Greece	Uveitis	25	+	+	-	+	?
Toussirot ¹⁴²	2001	Cross-sectional	France	Uveitis	71	+	+	-	?	+
Turan ¹⁴³	2008	Cross-sectional	Turkey	Uveitis	48	+	+	?	?	?
Van der Paard ¹⁴⁴	2002	Cross-sectional	Netherlands	Uveitis	106	+	+	?	?	+
Van der Paard ¹⁴⁵	2003	Cross-sectional	Netherlands	Uveitis	113	+	+	?	?	+
Van der Cruyssen ¹⁴⁶	2010	Cross-sectional	Belgium, Spain, Portugal and Ibero-American countries	Uveitis Psoriasis IBD	2718	+	+	+	?	+
Vander Cruyssen ¹⁴⁷	2007	Cross-sectional	Belgium	Uveitis Psoriasis IBD	847	+	+	+	?	+
Van der Heijde ¹⁴⁸	2005	Randomized controlled trial	USA Canada Europa	Uveitis Psoriasis IBD	279	+	+	-	+	?
Van der Heijde ¹⁴⁹	2005	Randomized controlled trial		Uveitis	387	+	+	-	+	?
Van der Heijde ¹⁵⁰	2006	Randomized controlled trial	USA Europe	Uveitis Psoriasis IBD	315	+	+	-	+	?

Vosse ¹⁵¹	2008	Case-control	UK	Psoriasis IBD	758	+	+	-	?	+
Ward ¹⁵²	2009	Cross-sectional	USA	Uveitis IBD	398	+	+	?	?	-
Weisman ¹⁵³	2010	Case-control	USA	Uveitis Psoriasis IBD	145	+	+	?	?	-
Will ¹⁵⁴	1990	Cross-sectional	UK	Uveitis Psoriasis IBD	1700	-	?	?	+	-
Woo ¹⁵⁵	2007	Cross-sectional	Korea	Uveitis	26	?	+	-	?	?
Zeng ¹⁵⁶	2003	Retrospective cohort	China	Uveitis	370	+	+	+	?	+

References

1. Aaron S, Miller ML, Howard J, et al. Complementation with HLA-A and HLA-D locus alleles in ankylosing spondylitis with peripheral arthritis. *Journal of Rheumatology* 1985;**12**:553-7.
2. Aggarwal A, Hissaria P, Misra R. Juvenile ankylosing spondylitis--is it the same disease as adult ankylosing spondylitis? *Rheumatology International* 2005;**25**:94-6.
3. Aggarwal R, Malaviya AN. Clinical characteristics of patients with ankylosing spondylitis in India. *Clinical Rheumatology* 2009;**28**:1199-205.
4. Agrawal S, Srivastava R, Sharma B, et al. IL1RN*2 allele of IL-1receptor antagonist VNTR polymorphism is associated with susceptibility to ankylosing [corrected] spondylitis in Indian patients. *Clinical Rheumatology* 2008;**27**:573-6.
5. al Attia HM, Sherif AM, Hossain MM, et al. The demographic and clinical spectrum of Arab versus Asian patients with ankylosing spondylitis in the UAE. *Rheumatology International* 1998;**17**:193-6.
6. Almodovar R, Zarco P, Collantes E, et al. Relationship between spinal mobility and disease activity, function, quality of life and radiology. A cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER). *Clinical & Experimental Rheumatology* 2009;**27**:439-45.
7. Aloush V, Ablin JN, Reitblat T, et al. Fibromyalgia in women with ankylosing spondylitis. *Rheumatology International* 2007;**27**:865-8.
8. Amor-Dorado JC, Barreira-Fernandez MP, Vazquez-Rodriguez TR, et al. Audiovestibular manifestations in patients with ankylosing spondylitis. *Medicine* 2011;**90**:99-109.
9. Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: A prospective longitudinal observational cohort study. *Arthritis Research and Therapy* 2011;**13**.
10. Askari A, Al-Bdour MD, Saadeh A, et al. Ankylosing spondylitis in north Jordan: descriptive and analytical study. *Annals of the Rheumatic Diseases* 2000;**59**:571-3.
11. Atagunduz P, Aydin SZ, Bahadir C, et al. Determinants of early radiographic progression in ankylosing spondylitis. *Journal of Rheumatology* 2010;**37**:2356-61.
12. Aydin SZ, Atagunduz P, Temel M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. *Rheumatology* 2008;**47**:142-4.
13. Baek HJ, Shin KC, Lee YJ, et al. Clinical features of adult-onset ankylosing spondylitis in Korean patients: patients with peripheral joint disease (PJD) have less severe spinal disease course than those without PJD. *Rheumatology* 2004;**43**:1526-31.
14. Bakland G, Nossent HC, Gran JT. Incidence and prevalence of ankylosing spondylitis in Northern Norway. *Arthritis & Rheumatism* 2005;**53**:850-5.
15. Beyeler C, Armstrong M, Bird HA, et al. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. *Annals of the Rheumatic Diseases* 1996;**55**:66-8.
16. Bodur H, Ataman S, Bugdayci DS, et al. Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP. *Rheumatol Int* 2012;**32**:169-76.

17. Bomtempo CADS, Lage RDC, Ferreira GA, et al. Clinical, laboratorial and radiographic evaluation in Brazilians with spondyloarthropaties. [Portuguese] Avaliacao clinica, laboratorial e radiografica de Brasileiros com espondiloartropatias. *Revista brasileira de reumatologia* 2006;**46**:238-45.
18. Boonen A, Chorus A, Miedema H, et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2001;**60**:1033-9.
19. Boonen A, van der Heijde D, Landewe R, et al. Costs of ankylosing spondylitis in three European countries: the patient's perspective. *Annals of the Rheumatic Diseases* 2003;**62**:741-7.
20. Boonen A, vander Cruyssen B, de Vlam K, et al. Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. *Journal of Rheumatology* 2009;**36**:1249-55.
21. Brandt J, Westhoff G, Rudwaleit M, et al. Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. [German] Validierung einer deutschen version des fragebogens BASDAI zur messung der krankheitsaktivitat bei ankylosierender spondylitis. *Zeitschrift fur Rheumatologie* 2003;**62**:264-73.
22. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. *Arthritis Rheum* 2003;**48**:1667-75.
23. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet* 2002;**359**:1187-93.
24. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. *Rheumatology* 2002;**41**:1280-5.
25. Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. *Arthritis Rheum* 2008;**58**:88-97.
26. Bremander A, Petersson IF, Bergman S, et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. *Arthritis care & research* 2011;**63**:550-6.
27. Brophy S, Pavy S, Lewis P, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. *Journal of Rheumatology* 2001;**28**:2667-73.
28. Brophy S, Mackay K, Al-Saidi A, et al. The natural history of ankylosing spondylitis as defined by radiological progression. *Journal of Rheumatology* 2002;**29**:1236-43.
29. Burgos-Vargas R, Naranjo A, Castillo J, et al. Ankylosing spondylitis in the Mexican mestizo: patterns of disease according to age at onset. *Journal of Rheumatology* 1989;**16**:186-91.
30. Calin A, Kennedy LG, Edmunds L, et al. Familial versus sporadic ankylosing spondylitis. Two different diseases? *Arthritis & Rheumatism* 1993;**36**:676-81.
31. Cansu DU, Calisir C, Savas Yavas U, et al. Predictors of radiographic severity and functional disability in Turkish patients with ankylosing spondylitis. *Clinical Rheumatology* 2011;**30**:557-62.
32. Carbone LD, Cooper C, Michet CJ, et al. Ankylosing spondylitis in Rochester, Minnesota, 1935-1989: Is the epidemiology changing? *Arthritis and Rheumatism* 1992;**35**:1476-82.

33. Chavan H, Samant R, Deshpande A, et al. Correlation of HLA B27 subtypes with clinical features of ankylosing spondylitis. *International Journal of Rheumatic Diseases* 2011;**14**:369-74.
34. Chen C-H, Lin K-C, Chen H-A, et al. Association of acute anterior uveitis with disease activity, functional ability and physical mobility in patients with ankylosing spondylitis: a cross-sectional study of Chinese patients in Taiwan. *Clinical Rheumatology* 2007;**26**:953-7.
35. Chen H-A, Chen C-H, Liao H-T, et al. Factors associated with radiographic spinal involvement and hip involvement in ankylosing spondylitis. *Seminars in Arthritis & Rheumatism* 2011;**40**:552-8.
36. Chen H-A, Chen C-H, Lin Y-J, et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. *Journal of Rheumatology* 2010;**37**:2126-32.
37. Chen HA, Chen CH, Liao HT, et al. Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. *Journal of Rheumatology* 2012;**39**:1013-8.
38. Choi ST, Kim JH, Kang EJ, et al. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. *Rheumatology* 2008;**47**:1775-9.
39. Cinar M, Dinc A, Simsek I, et al. Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study.[Erratum appears in *Rheumatol Int.* 2010 Jun;**30**(8):1141]. *Rheumatology International* 2010;**30**:331-40.
40. Coates LC, Cawkwell LS, Ng NWF, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. *Rheumatology* 2008;**47**:897-900.
41. Collantes E, Zarco P, Munoz E, et al. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. *Rheumatology* 2007;**46**:1309-15.
42. Cooper C, Carbone L, Michet CJ, et al. Fracture risk in patients with ankylosing spondylitis: a population based study. *Journal of Rheumatology* 1994;**21**:1877-82.
43. Davis JC, Jr., Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. *Arthritis & Rheumatism* 2003;**48**:3230-6.
44. de Juan MD, Reta A, Cancio J, et al. HLA-A*9, a probable secondary susceptibility marker to ankylosing spondylitis in Basque patients. *Tissue Antigens* 1999;**53**:161-6.
45. de Vries M, van der Horst-Bruinsma I, van Hoogstraten I, et al. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease.[Erratum appears in *J Rheumatol.* 2010 Dec;**37**(12):2639 Note: von Blomberg, Mary [corrected to von Blomberg, B Mary E]]. *Journal of Rheumatology* 2010;**37**:2340-4.
46. Dijkmans B, Emery P, Hakala M, et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis.[Erratum appears in *J Rheumatol.* 2010 Oct;**37**(10):2198]. *Journal of Rheumatology* 2009;**36**:1256-64.
47. Donnelly S, Doyle DV, Denton A, et al. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. *Annals of the Rheumatic Diseases* 1994;**53**:117-21.
48. Doran MF, Brophy S, MacKay K, et al. Predictors of longterm outcome in ankylosing spondylitis. *Journal of Rheumatology* 2003;**30**:316-20.

49. Dougados M, Braun J, Szanto S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). *Ann Rheum Dis* 2011;**70**:799-804.
50. Dougados M, d'Agostino MA, Benessiano J, et al. The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. *Joint Bone Spine* 2011;**78**:598-603.
51. Durmus D, Alayli G, Cengiz K, et al. Clinical significance of MEFV mutations in ankylosing spondylitis. *Joint, Bone, Spine: Revue du Rhumatisme* 2009;**76**:260-4.
52. Edmunds L, Elswood J, Calin A. New light on uveitis in ankylosing spondylitis. *Journal of Rheumatology* 1991;**18**:50-2.
53. El Maghraoui A, Bensabbah R, Bahiri R, et al. Cervical spine involvement in ankylosing spondylitis. *Clinical Rheumatology* 2003;**22**:94-8.
54. El Maghraoui A, Borderie D, Cherruau B, et al. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. *Journal of Rheumatology* 1999;**26**:2205-9.
55. El Mansouri L, Bahiri R, Abourazzak FE, et al. Two distinct patterns of ankylosing spondylitis in Moroccan patients. *Rheumatology International* 2009;**29**:1423-9.
56. Elswood J, Calin A, Berg C, et al. Ankylosing spondylitis. Comparative analysis of Swedish (n = 780) and British (n = 1500) experience--the National Ankylosing Spondylitis Societies. *Scand J Rheumatol* 1987;**16**:437-40.
57. Eustace S, Coughlan RJ, McCarthy C. Ankylosing spondylitis. A comparison of clinical and radiographic features in men and women. *Irish Medical Journal* 1993;**86**:120-2.
58. Feldtkeller E, Hammel L, Kellner H. Current trends in the therapy for ankylosing spondylitis - Results of a patient survey. [German] Aktuelle trends in diagnosestellung und therapie der spondylitis ankylosans - Ergebnisse einer patienten-befragung. *Aktuelle Rheumatologie* 2008;**33**:53-9.
59. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatology International* 2003;**23**:61-6.
60. Feldtkeller E, Vosse D, Geusens P, et al. Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitis. *Rheumatology International* 2006;**26**:234-9.
61. Fisher LR, Cawley MI, Holgate ST. Relation between chest expansion, pulmonary function, and exercise tolerance in patients with ankylosing spondylitis. *Annals of the Rheumatic Diseases* 1990;**49**:921-5.
62. Geirsson AJ, Eyjolfsdottir H, Bjornsdottir G, et al. Prevalence and clinical characteristics of ankylosing spondylitis in Iceland - a nationwide study. *Clinical & Experimental Rheumatology* 2010;**28**:333-40.
63. Gerard S, le Goff B, Maugars Y, et al. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients. *Joint, Bone, Spine: Revue du Rhumatisme* 2008;**75**:680-7.
64. Gladman DD, Brubacher B, Buskila D, et al. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. *Clinical & Investigative Medicine - Medecine Clinique et Experimentale* 1993;**16**:1-7.
65. Glasnovic M, Bosnjak I, Sram M, et al. Clinical characteristics of patients with spondyloarthritides and HLA-B27 positive antigen. *Collegium Antropologicum* 2011;**35**:397-402.

66. Goh L, Suresh P, Gafoor A, et al. Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. *Clinical Rheumatology* 2008;**27**:449-55.
67. Gonzalez S, Torre-Alonso JC, Martinez-Borra J, et al. TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patients. *Journal of Rheumatology* 2001;**28**:1288-93.
68. Gran JT, Husby G. Ankylosing spondylitis: a comparative study of patients in an epidemiological survey, and those admitted to a department of rheumatology. *Journal of Rheumatology* 1984;**11**:788-93.
69. Gran JT, Ostensen M, Husby G. A clinical comparison between males and females with ankylosing spondylitis. *Journal of Rheumatology* 1985;**12**:126-9.
70. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. *British Journal of Rheumatology* 1997;**36**:766-71.
71. Gunal EK, Sarvan FO, Kamali S, et al. Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. *Joint, Bone, Spine: Revue du Rhumatisme* 2008;**75**:299-302.
72. Guo ZS, Li C, Lin ZM, et al. Association of IL-1 gene complex members with ankylosing spondylitis in Chinese Han population. *International Journal of Immunogenetics* 2010;**37**:33-7.
73. Haibel H, Rudwaleit M, Braun J, et al. Six months open label trial of leflunomide in active ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2005;**64**:124-6.
74. Haibel H, Song IH, Rudwaleit M, et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice. *Clin Exp Rheumatol* 2008;**26**:247-52.
75. Hanova P, Pavelka K, Holcatova I, et al. Incidence and prevalence of psoriatic arthritis, ankylosing spondylitis, and reactive arthritis in the first descriptive population-based study in the Czech Republic. *Scandinavian Journal of Rheumatology* 2010;**39**:310-7.
76. Hascelik G, Oz B, Olmez N, et al. Association of macroscopic gut inflammation with disease activity, functional status and quality of life in ankylosing spondylitis. *Rheumatology International* 2009;**29**:755-8.
77. Harfouch EI, Al-Cheikh SA. HLA-B27 and its subtypes in Syrian patients with ankylosing spondylitis. *Saudi Medical Journal* 2011;**32**:364-8.
78. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? *Annals of the Rheumatic Diseases* 1998;**57**:135-40.
79. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. *Arthritis & Rheumatism* 2004;**51**:154-9.
80. Huang CH, Wei JCC, Hung PS, et al. Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. *Rheumatology* 2011;**50**:359-65.
81. Ho HH, Yeh SJ, Tsai WP, et al. Paroxysmal Supraventricular Tachycardia and Wolff-Parkinson-White Syndrome in Ankylosing Spondylitis: A Large Cohort Observation Study and Literature Review. *Semin Arthritis Rheum* 2012.
82. Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. *Journal of Rheumatology* 2001;**28**:554-9.

83. Inman RD, Davis JC, Jr., Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. *Arthritis Rheum* 2008;**58**:3402-12.
84. Inman RD, Maksymowych WP. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. *J Rheumatol* 2010;**37**:1203-10.
85. Islam SM, Numaga J, Fujino Y, et al. HLA-DR8 and acute anterior uveitis in ankylosing spondylitis. *Arthritis and Rheumatism* 1995;**38**:547-50.
86. Jaakkola E, Herzberg I, Laiho K, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2006;**65**:775-80.
87. Jang JH, Ward MM, Rucker AN, et al. Ankylosing spondylitis: patterns of radiographic involvement--a re-examination of accepted principles in a cohort of 769 patients. *Radiology* 2011;**258**:192-8.
88. Jimenez-Balderas FJ, Fernandez-Arrieta G, Camargo-Coronel A, et al. Uveitis in adult patients with rheumatic inflammatory autoimmune diseases at a tertiary-care hospital in Mexico City. *Journal of Rheumatology* 2011;**38**:325-30.
89. Jimenez-Balderas FJ, Martinez-Osuna P, Arellano J, et al. Does serum rheumatoid factor have an influence on the clinical picture of ankylosing spondylitis? *Clinical & Experimental Rheumatology* 1997;**15**:289-93.
90. Jimenez-Balderas FJ, Mintz G. Ankylosing spondylitis: clinical course in women and men. *Journal of Rheumatology* 1993;**20**:2069-72.
91. Jung SY, Park MC, Park YB, et al. Serum amyloid A as a useful indicator of disease activity in patients with ankylosing spondylitis. *Yonsei Medical Journal* 2007;**48**:218-24.
92. Jung KH, Kim TH, Sheen DH, et al. Associations of vitamin D binding protein gene polymorphisms with the development of peripheral arthritis and uveitis in ankylosing spondylitis. *Journal of Rheumatology* 2011;**38**:2224-9.
93. Kaijzel EL, Brinkman BM, van Krugten MV, et al. Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis. *Human Immunology* 1999;**60**:140-4.
94. Kidd B, Mullee M, Frank A, et al. Disease expression of ankylosing spondylitis in males and females. *Journal of Rheumatology* 1988;**15**:1407-9.
95. Kim TJ, Na KS, Lee HJ, et al. HLA-B27 homozygosity has no influence on clinical manifestations and functional disability in ankylosing spondylitis. *Clinical & Experimental Rheumatology* 2009;**27**:574-9.
96. Kim T-J, Kim T-H. Clinical spectrum of ankylosing spondylitis in Korea. *Joint, Bone, Spine: Revue du Rhumatisme* 2010;**77**:235-40.
97. Kim T-J, Kim T-H, Jun J-B, et al. Prevalence of ossification of posterior longitudinal ligament in patients with ankylosing spondylitis. *Journal of Rheumatology* 2007;**34**:2460-2.
98. Klingberg E, Carlsten H, Hilme E, et al. Calprotectin in ankylosing spondylitis--frequently elevated in feces, but normal in serum. *Scand J Gastroenterol* 2012;**47**:435-44.
99. Koh WH, Howe HS, Boey ML. Ankylosing spondylitis in Singaporean Chinese--a clinical profile. *Singapore Medical Journal* 1993;**34**:518-20.
100. Koh WH, Boey ML. Ankylosing spondylitis in Singapore: a study of 150 patients and a local update. *Annals of the Academy of Medicine, Singapore* 1998;**27**:3-6.
101. Lee HS, Kim TH, Yun HR, et al. Radiologic changes of cervical spine in ankylosing spondylitis. *Clinical Rheumatology* 2001;**20**:262-6.

102. Lee YH, Ji JD, Kim JS, et al. Ileocolonoscopy and histologic studies of Korean patients with ankylosing spondylitis. *Scandinavian Journal of Rheumatology* 1997;**26**:473-6.
103. Lee JY, Kim JI, Park JY, et al. Cervical spine involvement in longstanding ankylosing spondylitis. *Clinical & Experimental Rheumatology* 2005;**23**:331-8.
104. Lee J-H, Jun J-B, Jung S, et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. *Journal of Korean medical science* 2002;**17**:669-73.
105. Lin Y-C, Liang T-H, Chen W-S, et al. Differences between juvenile-onset ankylosing spondylitis and adult-onset ankylosing spondylitis. *Journal of the Chinese Medical Association: JCMA* 2009;**72**:573-80.
106. Magrey M, Khan MA. HLA-B27 homozygosity and clinical features of ankylosing spondylitis. *Current Rheumatology Reports* 2010;**12**:309-10.
107. Maki-Ikola O, Lehtinen K, Granfors K. Similarly increased serum IgA1 and IgA2 subclass antibody levels against *Klebsiella pneumoniae* bacteria in ankylosing spondylitis patients with/without extra-articular features. *British Journal of Rheumatology* 1996;**35**:125-8.
108. Maksymowych WP, Adlam N, Lind D, et al. Polymorphism of the LMP2 gene and disease phenotype in ankylosing spondylitis: no association with disease severity. *Clinical Rheumatology* 1997;**16**:461-5.
109. Maksymowych WP, Chou CT, Russell AS. Matching prevalence of peripheral arthritis and acute anterior uveitis in individuals with ankylosing spondylitis. *Annals of the Rheumatic Diseases* 1995;**54**:128-30.
110. Maksymowych WP, Jhangri GS, Gorodezky C, et al. The LMP2 polymorphism is associated with susceptibility to acute anterior uveitis in HLA-B27 positive juvenile and adult Mexican subjects with ankylosing spondylitis. *Annals of the Rheumatic Diseases* 1997;**56**:488-92.
111. Maksymowych WP, Mallon C, Richardson R, et al. Development and validation of the Edmonton Ankylosing Spondylitis Metrology Index. *Arthritis & Rheumatism* 2006;**55**:575-82.
112. Maksymowych WP, Russell AS. Polymorphism in the LMP2 gene influences the relative risk for acute anterior uveitis in unselected patients with ankylosing spondylitis. *Clinical & Investigative Medicine - Medecine Clinique et Experimentale* 1995;**18**:42-6.
113. Maksymowych WP, Salonen D, Inman RD, et al. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. *Journal of Rheumatology* 2010;**37**:1728-34.
114. Maksymowych WP, Tao S, Vaile J, et al. LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis. *Journal of Rheumatology* 2000;**27**:183-9.
115. Maksymowych WP, Wessler A, Schmitt-Egenolf M, et al. Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individuals. *Journal of Rheumatology* 1994;**21**:665-9.
116. Martindale J, Smith J, Sutton CJ, et al. Disease and psychological status in ankylosing spondylitis. *Rheumatology* 2006;**45**:1288-93.
117. Mierau R, von Muhlen CA, Zarnowski H, et al. Immunoglobulin allotype Gm(1,2;21) in ankylosing spondylitis with peripheral arthritis. *Annals of the Rheumatic Diseases* 1988;**47**:893-7.
118. Muntean L, Rojas-Vargas M, Font P, et al. Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis. *Clinical Rheumatology* 2011;**30**:691-5.
119. Nazarinia MA, Ghaffarpasand F, Heiran HR, et al. Pattern of ankylosing spondylitis in an Iranian population of 98 patients. *Modern Rheumatology* 2009;**19**:309-15.

120. Ozgocmen S, Ardicoglu O, Kamanli A, et al. Pattern of disease onset, diagnostic delay, and clinical features in juvenile onset and adult onset ankylosing spondylitis. *Journal of Rheumatology* 2009;**36**:2830-3.
121. Paardt Mvd, Dijkmans B, Giltay E, et al. Dutch patients with familial and sporadic ankylosing spondylitis do not differ in disease phenotype. *Journal of Rheumatology* 2002;**29**:2583-4.
122. Park S-H, Kim J, Kim S-G, et al. Human leucocyte antigen-B27 subtypes in Korean patients with ankylosing spondylitis: higher B*2705 in the patient group. *International Journal of Rheumatic Diseases* 2009;**12**:34-8.
123. Pham T, Landewe R, van der Linden S, et al. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2006;**65**:1620-5.
124. Piergiacomini G, Agostinelli M, Baccarini V, et al. [Anterior uveitis in ankylosing spondylitis. A retrospective study]. *Revue du Rhumatisme et des Maladies Osteo-Articulaires* 1988;**55**:979-82.
125. Costa J, Vieira-Sousa E, Rábias S, et al. Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts. *Clinical Rheumatology* 2012;**31**:447-54.
126. Prakash S, Mehra NK, Bhargava S, et al. Ankylosing spondylitis in North India: a clinical and immunogenetic study. *Annals of the Rheumatic Diseases* 1984;**43**:381-5.
127. Prati C, Racadot E, Cedoz J-P, et al. Thrombin generation in ankylosing spondylitis. *Clinical Rheumatology* 2011;**30**:511-4.
128. Rahman P, Inman RD, Gladman DD, et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. *Arthritis & Rheumatism* 2008;**58**:1020-5.
129. Robertson LP, Davis MJ. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. *Rheumatology* 2004;**43**:1565-8.
130. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. *Arthritis & Rheumatism* 2009;**60**:717-27.
131. Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. *J Rheumatol* 2009;**36**:801-8.
132. Sambrook P, McGuigan L, Champion D, et al. Clinical features and followup study of HLA-B27 positive patients presenting with peripheral arthritis. *Journal of Rheumatology* 1985;**12**:526-8.
133. Sampaio-Barros PD, Conde RA, Bonfiglioli R, et al. Characterization and outcome of uveitis in 350 patients with spondyloarthropathies. *Rheumatology International* 2006;**26**:1143-6.
134. Sampaio-Barros PD, Bertolo MB, Kraemer MH, et al. Primary ankylosing spondylitis: patterns of disease in a Brazilian population of 147 patients. *Journal of Rheumatology* 2001;**28**:560-5.
135. Sanmarti R, Ercilla MG, Brancos MA, et al. HLA class II antigens (DR, DQ loci) and peripheral arthritis in ankylosing spondylitis. *Annals of the Rheumatic Diseases* 1987;**46**:497-500.
136. Saougou I, Markatseli TE, Voulgari PV, et al. Maintained clinical response of infliximab treatment in ankylosing spondylitis: A 6-year long-term study. *Joint Bone Spine* 2010;**77**:325-9.

137. Shukla S, Misra R, Agarwal V. Pulse Pamidronate therapy in NSAID refractory ankylosing spondylitis. Is it effective?-An open label study. *Indian Journal of Rheumatology* 2010;**5**:171-5.
138. Singh G, Lawrence A, Agarwal V, et al. Higher prevalence of extra-articular manifestations in ankylosing spondylitis with peripheral arthritis. *JCR: Journal of Clinical Rheumatology* 2008;**14**:264-6.
139. Skare TL, Silva TQ, Pastro PC. [Uveitis and spondyloarthritis: prevalence and relationship with joint disease]. *Arquivos Brasileiros de Oftalmologia* 2007;**70**:827-30.
140. Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. *J Rheumatol* 2001;**28**:1605-14.
141. Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. *Ann Rheum Dis* 2003;**62**:1218-20.
142. Toussiro E, Michel F, Wendling D. Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. *Rheumatology* 2001;**40**:882-8.
143. Turan Y, Duruoz MT, Cerrahoglu L. Clinical and radiological characteristics of spondyloarthropathy. [Turkish] Spondiloartropatili hastalarin klinik ve radyolojik ozellikleri. *Romatizma* 2008;**23**:46-51.
144. van der Paardt M, Crusius JBA, Garcia-Gonzalez MA, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. *Rheumatology* 2002;**41**:1419-23.
145. van der Paardt M, Crusius JBA, de Koning MHMT, et al. CARD15 gene mutations are not associated with ankylosing spondylitis. *Genes & Immunity* 2003;**4**:77-8.
146. Vander Cruyssen B, Munoz-Gomariz E, Font P, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. *Rheumatology* 2010;**49**:73-81.
147. Vander Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. *Ann Rheum Dis* 2007;**66**:1072-7.
148. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum* 2005;**52**:582-91.
149. van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. *Arthritis Rheum* 2005;**52**:1205-15.
150. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2006;**54**:2136-46.
151. Vosse D, Landewe R, Garnero P, et al. Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. *Rheumatology* 2008;**47**:1219-22.
152. Ward MM, Hendrey MR, Malley JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. *Arthritis & Rheumatism* 2009;**61**:859-66.

153. Weisman MH, Chen L, Clegg DO, et al. Development and validation of a case ascertainment tool for ankylosing spondylitis. *Arthritis care & research* 2010;**62**:19-27.
154. Will R, Edmunds L, Elswood J, et al. Is there sexual inequality in ankylosing spondylitis? A study of 498 women and 1202 men. *Journal of Rheumatology* 1990;**17**:1649-52.
155. Woo J-H, Lee H-J, Sung I-H, et al. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. *Journal of Rheumatology* 2007;**34**:1753-9.
156. Zeng QY. Ankylosing spondylitis in Shantou, China: 15 years' clinical experience. *Journal of Rheumatology* 2003;**30**:1816-21.